James Anderson: investors must pay "high multiples" for tech stocks
Investors must be willing to pay “unreasonable prices” for high-tech growth stocks to take advantage of the huge potential returns that these companies can deliver, says James Anderson, the co-manager of the £13.5bn Scottish Mortgage Investment Trust.
Many investors shrink from the valuations of firms such as Amazon and Tesla – which are Scottish Mortgage’s two largest positions – because they are obsessed with value investing or with tracking the market cheaply, he tells the Financial Times. But both these approaches badly misunderstand what drives long-term returns.
“All the excess returns in world markets since 1990 have come from just 1.3% of companies,” says Anderson, citing research by Hendrik Bessembinder, professor of finance at Arizona State University. Outsize growth is concentrated among a tiny number of stocks. For these, “we need to be willing to pay high multiples of immediate earnings because the scale of future potential returns can be so dramatic”, he says. “The valuation will turn out to be [very] low on the stocks that flourish. On the others, we will lose money.”
Baillie Gifford last week sold part of its stake in Tesla, but this was purely because it had risen so much in value that it breached limits of how much of a portfolio can be in a single stock. Anderson remains optimistic about Tesla’s prospects – and about the potential for tech to transform the world. “Over the past 15 years we have made an awful lot of mistakes,” he says. “But our biggest mistake may be that we have not been optimistic enough.”
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Sign up to Money Morning
Our team, led by award winning editors, is dedicated to delivering you the top news, analysis, and guides to help you manage your money, grow your investments and build wealth.
-
8 of the best properties for sale with indoor swimming pools
The best properties for sale with indoor swimming pools – from an award-winning contemporary house in East Sussex, to a converted barn in Hampshire
By Natasha Langan Published
-
Chinese stocks slump on first trading day of 2025
Chinese stocks suffered in the new year from their worst first day of trading since 2016, despite a state stimulus package
By Alex Rankine Published
-
Why Wise could be worth a lot more than its share price implies
Foreign-exchange transfer service Wise has the potential to become the Amazon of its sector – here's why you should consider buying this stock now
By Jamie Ward Published
-
Can The Gym Group pump up your portfolio?
Gym Group was one of the best UK small-cap stocks in 2024 and will beef up your profits this New Year
By Rupert Hargreaves Published
-
MoneyWeek's five predictions for investors in 2025
MoneyWeek's City columnist gazes into his crystal ball and sees five unexpected events in store for investors in 2025
By Matthew Lynn Published
-
How buy-and-build stocks deliver strong returns
Bunzl, DCC and Diploma became successful through buy-and-build – rolling up dozens of unglamorous businesses. How does it work and what makes it successful?
By Jamie Ward Published
-
Singapore Technologies Engineering shows strong growth
Singapore Technologies Engineering offers diversification, improving profitability and income
By Dr Mike Tubbs Published
-
Royal Mail takeover by Czech billionaire approved for £3.6bn
Royal Mail is now owned by Czech billionaire Daniel Kretinsky, following a £3.6 billion takeover
By Dr Matthew Partridge Published
-
Will AI be the future of advertising?
It remains to be seen, but the idea that AI providers can make money from advertising does not bode well
By Matthew Lynn Published
-
AstraZeneca goes cheap – should you buy?
The decline in AstraZeneca’s share price is overdone given the outlook, and the stock is cheap
By Rupert Hargreaves Published